IDT Corp (IDT)

15.36
0.50 3.20
NYSE : Technology
Prev Close 15.86
Open 15.97
Day Low/High 15.29 / 16.01
52 Wk Low/High 11.78 / 23.13
Volume 259.30K
Avg Volume 231.80K
Exchange NYSE
Shares Outstanding 23.10M
Market Cap 353.87M
EPS 1.00
P/E Ratio 9.23
Div & Yield 0.76 (5.00%)

Latest News

IDT Named Top Dividend Stock With Insider Buying and 5.13% Yield (IDT)

IDT Named Top Dividend Stock With Insider Buying and 5.13% Yield (IDT)

In this series, we look through the most recent Dividend Channel ''DividendRank'' report, and then we cherry pick only those companies that have experienced insider buying within the past six months. The officers and directors of a company tend to have a unique insider's view of the business, and presumably the only reason an insider would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both.

Straight Path Shares Rocket on News Another Suitor Might Outbid AT&T

Straight Path Shares Rocket on News Another Suitor Might Outbid AT&T

Is Verizon also interested in Straight Path and its millimeter wave wireless spectrum?

Top Buys by Top Brass: Chairman of the Board Jonas's $10M Bet on IDT

Top Buys by Top Brass: Chairman of the Board Jonas's $10M Bet on IDT

A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both.

AT&T Spends $1.6B to Upgrade Its 5G Wireless Plan

AT&T Spends $1.6B to Upgrade Its 5G Wireless Plan

Buying Straight Path gives AT&T wireless spectrum to connect cars, medical devices and other gadgets to wireless networks.

FDA Provides Cornerstone Pharmaceuticals Approval To Initiate Pivotal Study For CPI-613, Its Metabolism-Directed Anticancer Compound

FDA Provides Cornerstone Pharmaceuticals Approval To Initiate Pivotal Study For CPI-613, Its Metabolism-Directed Anticancer Compound

Successful End-of-Phase I Type B Meetings with FDA Clears Way for Pivotal Trials in Acute Myeloid Leukemia (AML) and Pancreatic Cancer

Cash Dividend On The Way From IDT

Cash Dividend On The Way From IDT

Looking at the universe of stocks we cover at Dividend Channel, on 3/15/17, IDT Corp will trade ex-dividend, for its quarterly dividend of $0.19, payable on 3/24/17. As a percentage of IDT's recent stock price of $13.06, this dividend works out to approximately 1.45%, so look for shares of IDT Corp to trade 1.45% lower — all else being equal — when IDT shares open for trading on 3/15/17.

IDT Enters Oversold Territory

IDT Enters Oversold Territory

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. IDT Corp presently has a stellar rank, in the top 10% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

IDT Makes Notable Cross Below Critical Moving Average

IDT Makes Notable Cross Below Critical Moving Average

In trading on Tuesday, shares of IDT Corp crossed below their 200 day moving average of $17.07, changing hands as low as $15.66 per share. IDT Corp shares are currently trading off about 15.1% on the day.

Noteworthy Monday Option Activity: IDT, GPRO, SBUX

Noteworthy Monday Option Activity: IDT, GPRO, SBUX

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in IDT Corp , where a total volume of 914 contracts has been traded thus far today, a contract volume which is representative of approximately 91,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 69% of IDT's average daily trading volume over the past month, of 132,480 shares.

BOSS Revolution Releases Major Update To Its Popular Calling App

BOSS Revolution Releases Major Update To Its Popular Calling App

Now Includes FREE App2App Calling and Messaging

Noteworthy Friday Option Activity: IDT, CECO, EVC

Noteworthy Friday Option Activity: IDT, CECO, EVC

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in IDT Corp , where a total volume of 561 contracts has been traded thus far today, a contract volume which is representative of approximately 56,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 59.1% of IDT's average daily trading volume over the past month, of 94,930 shares.

IDT Introduces The BOSS Revolution Money App

IDT Introduces The BOSS Revolution Money App

Send Money, Airtime and Gifts - Quickly, Easily and Securely

National Retail Solutions (NRS) Partners With Jetro

National Retail Solutions (NRS) Partners With Jetro

Jetro Will Offer NRS' POS Terminals in All Jetro Stores.

IDT Passes Through 4% Yield Mark

IDT Passes Through 4% Yield Mark

Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of IDT Corp were yielding above the 4% mark based on its quarterly dividend (annualized to $0.76), with the stock changing hands as low as $18.70 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return.

PicuP Goes Live

PicuP Goes Live

PicuP - A New Cloud Based Phone Service - Offers Free and Ultra-Affordable Plans for Start-Up Businesses

NRS Achieves Success Helping Independent Retailers Compete

NRS Achieves Success Helping Independent Retailers Compete

Over 1700 POS Terminals Deployed in 2016 in Major Cities Across the Country with Growth Expected to Accelerate in 2017

Net2phone Acquires LiveNinja

Net2phone Acquires LiveNinja

net2phone's Rapidly Growing Cloud Based Phone Service - PicuP - Will Leverage LiveNinja's Messaging and Live Chat Services to Provide SMBs with a Comprehensive Communications Solution

Cornerstone Pharmaceuticals To Present At 9th Annual Biotech Showcase™ In San Francisco, January 9-11, 2017

Cornerstone Pharmaceuticals To Present At 9th Annual Biotech Showcase™ In San Francisco, January 9-11, 2017

Biotech Showcase™ Occurs Concurrently to the 35th Annual JP Morgan Healthcare Conference - an Ideal Venue for Cornerstone Pharmaceuticals to Present its Exciting Corporate Vision and Unique Oncology Therapeutic Platform

Cornerstone Pharmaceuticals To Present At 9th Annual Biotech Showcase™ In San Francisco, January 9-11, 2017

Cornerstone Pharmaceuticals To Present At 9th Annual Biotech Showcase™ In San Francisco, January 9-11, 2017

Biotech Showcase™ Occurs Concurrently to the 35th Annual JP Morgan Healthcare Conference - an Ideal Venue for Cornerstone Pharmaceuticals to Present its Exciting Corporate Vision and Unique Oncology Therapeutic Platform

Ex-Div Reminder for IDT

Ex-Div Reminder for IDT

Looking at the universe of stocks we cover at Dividend Channel, on 12/15/16, IDT Corp will trade ex-dividend, for its quarterly dividend of $0.19, payable on 12/23/16. As a percentage of IDT's recent stock price of $19.50, this dividend works out to approximately 0.97%, so look for shares of IDT Corp to trade 0.97% lower — all else being equal — when IDT shares open for trading on 12/15/16.

How To YieldBoost IDT Corp To 13.2% Using Options

How To YieldBoost IDT Corp To 13.2% Using Options

Shareholders of IDT Corp looking to boost their income beyond the stock's 3.7% annualized dividend yield can sell the June 2017 covered call at the $22.50 strike and collect the premium based on the $1.00 bid, which annualizes to an additional 9.5% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost), for a total of 13.2% annualized rate in the scenario where the stock is not called away. Any upside above $22.50 would be lost if the stock rises there and is called away, but IDT shares would have to advance 11.2% from current levels for that to happen, meaning that in the scenario where the stock is called, the shareholder has earned a 16.2% return from this trading level, in addition to any dividends collected before the stock was called.

How To YieldBoost IDT Corp To 13.2% Using Options

How To YieldBoost IDT Corp To 13.2% Using Options

Shareholders of IDT Corp looking to boost their income beyond the stock's 3.7% annualized dividend yield can sell the June 2017 covered call at the $22.50 strike and collect the premium based on the $1.00 bid, which annualizes to an additional 9.5% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost), for a total of 13.2% annualized rate in the scenario where the stock is not called away. Any upside above $22.50 would be lost if the stock rises there and is called away, but IDT shares would have to advance 11.2% from current levels for that to happen, meaning that in the scenario where the stock is called, the shareholder has earned a 16.2% return from this trading level, in addition to any dividends collected before the stock was called.

Cornerstone Pharmaceuticals, Inc. Presents Phase I Data On CPI-613 In Acute Myeloid Leukemia (AML) And T-Cell Non-Hodgkin's Lymphoma (T-cell NHL) At ASH 2016

Cornerstone Pharmaceuticals, Inc. Presents Phase I Data On CPI-613 In Acute Myeloid Leukemia (AML) And T-Cell Non-Hodgkin's Lymphoma (T-cell NHL) At ASH 2016

First Reported Studies of CPI-613-based Combination Therapy in these Difficult-to-Treat Malignancies Show Encouraging Efficacy and Safety Results

Cornerstone Pharmaceuticals Appoints Brian Mullaney, M.D., Ph.D., As Chief Medical Officer

Cornerstone Pharmaceuticals Appoints Brian Mullaney, M.D., Ph.D., As Chief Medical Officer

Extensive track record in oncology clinical development strengthens Cornerstone's drug development and commercialization capabilities